Lamivudine plus dolutegravir improves bone mineral density compared to emtricitabine/tenofovir alafenamide plus an integrase inhibitor

2021 ◽  
Author(s):  
Arturo Ciccullo ◽  
Gianmaria Baldin ◽  
Vanni Borghi ◽  
Anna Pia Lassandro ◽  
Damiano Farinacci ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Integrase Inhibitor ◽  
Mineral Density ◽  
Tenofovir Alafenamide

A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection

2017 ◽  
Vol 31 (2) ◽  
pp. 216-221 ◽  
Author(s):  
Sara A. Angione ◽  
Sibyl M. Cherian ◽  
Ayşe Elif Özdener
Keyword(s):  
Bone Mineral Density ◽  
Adverse Events ◽  
Renal Impairment ◽  
Bone Mineral ◽  
Metabolic Effects ◽  
Efficacy And Safety ◽  
Mineral Density ◽  
Single Tablet Regimen ◽  
Tenofovir Alafenamide ◽  
Hiv 1

Introduction: This review evaluates the efficacy and safety of Genvoya® (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide [EVG/c/TAF/FTC]), a single-tablet regimen used for the management of HIV-1 infection. Phase II and III randomized clinical trials evaluate the efficacy and safety of EVG/c/TAF/FTC and tenofovir disoproxil fumerate (TDF)–containing arms; renal impairment, bone mineral density, metabolic effects, and other adverse events are topics explored within this review. Methods: A MEDLINE with full text and PubMed literature search was conducted for the past 5 years, up to April 2016. Results: Virologic suppression was similar between the EVG/c/TAF/FTC and TDF-containing groups (<50 copies/mL) at week 48. The bone mineral density in the hip and spine showed a significant reduction in the TDF-containing groups. The glomerular filtration rate increased in patients in the EVG/c/TAF/FTC arm and there were significant differences in total proteinuria, albuminuria, and tubular proteinuria in patients switching to EVG/c/TAF/FTC. The most common adverse events were diarrhea, nausea, and headache. Discussion: The coformulated Genvoya regimen is well tolerated and effective in treatment-naive and virologically suppressed patients. Data seem to suggest it may also be effective and safe in patients with mild to moderate renal impairment. The lower-dosed single-tablet regimen has significantly reduced bone and renal side effects.

Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study

2019 ◽  
Vol 74 (9) ◽  
pp. 2742-2751 ◽  
Author(s):  
Christine Katlama ◽  
Lambert Assoumou ◽  
Marc-Antoine Valantin ◽  
Cathia Soulié ◽  
Esteban Martinez ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Success Rate ◽  
Bone Mineral ◽  
Viral Suppression ◽  
Dual Therapy ◽  
Integrase Inhibitor ◽  
Mineral Density ◽  
Type 1 Error ◽  
Virological Success ◽  
High Level

Abstract Background Dual therapy combining integrase inhibitors and NNRTIs represents a promising regimen in ageing HIV-infected individuals with long exposure to nucleoside analogues and PIs. Methods The ANRS 163 ETRAL trial (NCT02212379) was a 96 week, multicentre, single-arm study evaluating the efficacy and safety of raltegravir (400 mg twice daily)/etravirine (200 mg twice daily) in individuals >45 years, on a PI-containing regimen who were integrase inhibitor and etravirine naive. The primary endpoint was the proportion of participants with virological success, defined by the absence of virological failure up to week 48. Main secondary outcomes included evolution of metabolic parameters, CD4/CD8 count, bone mineral density and inflammatory markers. The study was designed to show an efficacy >90%, assuming a success rate ≥95%, with a power of 80% and a 5% type-1 error. Results One hundred and sixty-five participants (median age 52 years, duration of ART 16.9 years, viral suppression 6.9 years and CD4 count 700 cells/mm3) were enrolled. By ITT analysis, viral suppression was maintained in 99.4% of participants (95% CI = 95.6%–99.9%) at week 48 and 98.7% (95% CI = 95.0%–99.7%) at week 96. Two virological failures occurred (week 24 and week 64) without emergence of integrase inhibitor resistance. Eight participants discontinued raltegravir/etravirine for adverse events, leading to a strategy success rate of 95.1% (95% CI = 90.5%–97.5%) at week 48 and 92.7% (95% CI = 87.5%–95.8%) at week 96. Over 96 weeks, lipid fractions improved (P < 0.001), CD4/CD8 ratio increased, IFNγ-induced protein 10 (IP-10) decreased (−8.1%), soluble CD14 decreased (−27%, P < 0.001) bone mineral density improved and BMI increased. Conclusions Raltegravir plus etravirine dual therapy demonstrated durable efficacy in virologically suppressed ageing patients.

Relationship between serum calcium levels and bone mineral density in liver transplant receipients

2001 ◽  
Vol 120 (5) ◽  
pp. A564-A564
Author(s):  
K ISLAM ◽  
S CREECH ◽  
R SOKHI ◽  
R KONDAVEETI ◽  
A NADIR ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Liver Transplant ◽  
Bone Mineral ◽  
Serum Calcium ◽  
Mineral Density

130: Role of Calcium Intake on Bone Mineral Density in Rostate Cancer Patients Under Androgen Deprivation Therapy

2006 ◽  
Vol 175 (4S) ◽  
pp. 41-42
Author(s):  
Anna Orsola ◽  
Jacques Planas ◽  
Carlos Salvador ◽  
José M. Abascal ◽  
Enrique Trilla ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Cancer Patients ◽  
Androgen Deprivation Therapy ◽  
Bone Mineral ◽  
Calcium Intake ◽  
Androgen Deprivation ◽  
Mineral Density ◽  
Rostate Cancer
Sign in / Sign up

Export Citation Format

Share Document